S. Billecke

发表

Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R.

B. La Du, C. Bisgaier, M. Aviram, 1998, Arteriosclerosis, thrombosis, and vascular biology.

The Role of hsp90 in Heme-dependent Activation of Apo-neuronal Nitric-oxide Synthase*

W. Pratt, P. Murphy, Y. Morishima, 2004, Journal of Biological Chemistry.

Proteolytic Degradation of Nitric Oxide Synthase: Effect of Inhibitors and Role of hsp90-Based Chaperones

E. Lowe, S. Billecke, Y. Osawa, 2003, Journal of Pharmacology and Experimental Therapeutics.

Blood content of asymmetric dimethylarginine: new insights into its dysregulation in renal disease.

C. Gadegbeku, K. Jamerson, S. Whitesall, 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Asymmetrical dimethylarginine plasma clearance persists after acute total nephrectomy in rats.

S. Whitesall, L. D'alecy, Katari A Carello, 2006, American journal of physiology. Heart and circulatory physiology.

Contribution of whole blood to the control of plasma asymmetrical dimethylarginine.

M. Kimoto, S. Whitesall, L. D'alecy, 2006, American journal of physiology. Heart and circulatory physiology.

On the physiological role(s) of the paraoxonases.

T. Standiford, M. Navab, B. La Du, 1999, Chemico-biological interactions.

Rabbits possess a serum paraoxonase polymorphism similar to the human Q192R.

C. Watson, B. La Du, C. Bisgaier, 2001, Pharmacogenetics.

Pheochromocytoma presenting with Takotsubo syndrome.

P. Marcovitz, S. Billecke, P. Czako, 2010, Journal of interventional cardiology.

Properties of the retained N-terminal hydrophobic leader sequence in human serum paraoxonase/arylesterase.

B. La Du, C. Bisgaier, M. Aviram, 1999, Chemico-biological interactions.

Activities : Selective Action of Human Paraoxonase Allozymes Q and R Sulfhydryl Group and Is Different from That Required for Its Arylesterase/paraoxonase Paraoxonase Active Site Required for Protection against Ldl Oxidation Involves Its Free

C. Bisgaier, Cary Hsu, M. Aviram, 2022 .

Metabolism-based inactivation of neuronal nitric-oxide synthase by components of cigarette and cigarette smoke.

D. Demady, Y. Kamada, E. Lowe, 2003, Drug metabolism and disposition: the biological fate of chemicals.

Serum paraoxonase (PON1) isozymes: the quantitative analysis of isozymes affecting individual sensitivity to environmental chemicals.

R. Haley, B. La Du, C. Broomfield, 2001, Drug metabolism and disposition: the biological fate of chemicals.

Estrogen esters as substrates for human paraoxonases.

B. La Du, D. Draganov, J. Teiber, 2007, Archives of biochemistry and biophysics.

Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants.

B. La Du, S Billecke, M Aviram, 1999, Free radical biology & medicine.

Usefulness of breast arterial calcium detected on mammography for predicting coronary artery disease or cardiovascular events in women with angina pectoris and/or positive stress tests.

M. Yerkey, M. Rebner, P. Marcovitz, 2010, The American journal of cardiology.

Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters.

C Watson, P. Stetson, R. Counsell, 2000, Drug metabolism and disposition: the biological fate of chemicals.

hsp90 Is Required for Heme Binding and Activation of Apo-Neuronal Nitric-oxide Synthase

W. Pratt, A. Bender, K. C. Kanelakis, 2002, The Journal of Biological Chemistry.

Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids : apolipoprotein A-I stabilizes activity.

B. La Du, C. Bisgaier, M. Aviram, 1999, Arteriosclerosis, thrombosis, and vascular biology.

Increased plasma cholinesterase activity and mivacurium resistance: report of a family.

D. Bevan, B. La Du, C. Watson, 1999, Anesthesia and analgesia.

Rabbit Serum Paraoxonase 3 (PON3) Is a High Density Lipoprotein-associated Lactonase and Protects Low Density Lipoprotein against Oxidation*

P. Stetson, C. Watson, B. La Du, 2000, The Journal of Biological Chemistry.

Nitric oxide synthase, ADMA, SDMA, and nitric oxide activity in the paraventricular nucleus throughout the etiology of renal wrap hypertension.

C. Hinojosa-Laborde, J. Haywood, K. Patel, 2012, American journal of physiology. Heart and circulatory physiology.

Characterization of a soluble mouse liver enzyme capable of hydrolyzing diisopropyl phosphorofluoridate.

J. Doorn, B. La Du, C. Broomfield, 1999, Chemico-biological interactions.

Putting the Benefits and Risks of Aerobic Exercise in Perspective

B. Franklin, S. Billecke, 2012, Current sports medicine reports.

Massive quantities of asymmetric dimethylarginine (ADMA) are incorporated in red blood cell proteins and may be released by proteolysis following hemolytic stress.

L. D'alecy, S. Billecke, 2010, Blood cells, molecules & diseases.

Injury or Activity-Related Pain Sustained by a Population of At-Risk Women during a 6-Month Exercise Program

B. Franklin, M. Donnelly, P. Marcovitz, 2013, The Physician and sportsmedicine.

Long-term safety and efficacy of telmisartan/amlodipine single pill combination in the treatment of hypertension

P. Marcovitz, S. Billecke, 2013, Vascular health and risk management.

Pitfalls in the assessment of PON1 status in clinical populations.

J. Teiber, S. Billecke, 2011, Fertility and sterility.

Evidence that several conserved histidine residues are required for hydrolytic activity of human paraoxonase/arylesterase.

J. Doorn, B. La Du, S. Billecke, 1999, Chemico-biological interactions.

Association of low PON1 type Q (type A) arylesterase activity with neurologic symptom complexes in Gulf War veterans.

R. Haley, B. La Du, S. Billecke, 1999, Toxicology and applied pharmacology.

Ubiquitination and Degradation of Neuronal Nitric-Oxide Synthase in Vitro: Dimer Stabilization Protects the Enzyme from Proteolysis

Gary J. Jenkins, Y. Kamada, E. Lowe, 2004, Molecular Pharmacology.

Proteolytic Degradation of Nitric Oxide Synthase: Effect of Inhibitors and Role of hsp90-Based Chaperones

E. Lowe, S. Billecke, Y. Osawa, 2003, Journal of Pharmacology and Experimental Therapeutics.